Hey everybody this is Alex and you are listening to Equity Monday from November 23rd, 2020.

Welcome to your Tech and Startups and Venture Capital Primer for the week, and welcome to a holiday

week here in the U.S.

Now, no, you don't have to care about American

Thanksgiving a feast day but it will impact the news flow that we'll see over the

next few days and by that I mean theoretically things should slow down.

But don't bet your house on it.

A lot of things that were supposed to be true have wound up untrue in 2020, like companies

avoiding going public during an election year.

Thus far in 2020, we've had Unicorns going public all over an election year. Thus far in 2020 we've had unicorns going public all over an election cycle and one that has

been more fractious than most in my nation's history.

You get the idea.

But there's still so much to get through, so let's dig into the weekend and also take a look at the latest most important

funding rounds.

Now over the weekend the key business story appears to be good results from a third

vaccine candidate this time from AstraZeneca which has a vaccine that is around

70% effective. The AstraZeneca news comes after vaccines from

Moderna and Pfizer biointec that demonstrated that they were even more

effective. So as you've already guessed on the back of more good news about the pandemic eventually coming to a close,

stocks are set to rise here in the US.

Now if you're struggling to Grockwise, stocks rise on good vaccine news and don't seem to fall on bad COVID-19 news let me help

good vaccine news helps investors bet more on a quick conclusion to the

...